The accompanying notes are an integral part of the consolidated financial statements.
Consolidated Statements of Changes in Equity (cont’d)
Consolidated Statements of Cash Flows (cont’d)
Notes to the Consolidated Financial Statements as at December 31, 2021
Note 1 – General (cont’d)
Effects of the spreading of the coronavirus (cont’d):
Material events in the reporting period
In December 2021, Talasol Project entered into a New Facilities Agreement with European institutional lenders (the “Talasol New Facilities Agreement”). The Talasol New Facilities Agreement provides for the provision of a term loan facility in two tranches: (i) a term loan in the amount of €155 million for 22.5 years, and (ii) a term loan in the amount of €20 million for 21 years (together, the “New Financing”). The aggregate New Financing amount (€175 million), will be used by Talasol to repay the current outstanding project finance debt of Talasol in the amount of €121 million (the “Current Financing”). The New Financing bears a fixed annual interest rate at a weighted average of approximately 3%, compared to a variable interest rate that was fixed at an average of approximately 3% by an interest rate swap contract in the Current Financing. Out of the New Financing amount, €6.9 million will be deposited in Talasol’s account as a debt service fund and €10 million will be deposited in Talasol’s bank account as security for a letter of credit to the PPA provider (the “PPA Security Fund”). The PPA Security Fund will be reduced by €1 million every year, up to a minimum amount of €3.5 million, which will be released at the expiration of the PPA
Note 2 –Basis of Preparation (cont’d)
Basis of preparation of the financial statements (cont’d)
Significant accounting judgments, estimates and assumptions used in the preparation of the financial statements (cont’d)
Determination of fair value (cont’d):
Change in classification
The Company is examining the effects of the Amendment on the financial statements with no plans for early adoption.
The Company is examining the effects of the Amendment on the financial statements and estimates no effects on the financial statements.
The Company is examining the effects of the Amendment on the financial statements with no plans for early adoption
Note 6 - Investee Companies and other investments (cont'd)
Equity accounted investees (cont'd)
U. Dori Energy Infrastructures Ltd. (“Dori Energy”) (cont’d)–
Petition to Approve a Derivative Claim filed by Dori Energy (cont’d)
Opening Motion filed by Zorlu (cont’d)
Note 6 - Investee Companies and other investments (cont’d)
Pumped Storage Projects (cont’d)
B.
Development of PV Projects in Italy (cont’d)
Second Framework Agreement (cont’d)
Subsidiaries - (cont’d)
Biogas Projects in the Netherlands (cont'd)
D.
2.
PV Projects in Spain (cont’d)
The Talasol Project (cont'd) -
The Talasol Project (cont’d) -
The uses of the Talasol New Financing amount are as follows: (1) prepayment of the outstanding €121 million amount of the Talasol Previous Financing; (2) deposit of €6.9 million in Talasol’s bank account as a debt service fund; (3) deposit of €10 million in Talasol’s bank account as security for a letter of credit to the PPA provider (the “Talasol PPA Security Fund”) (4) unwinding of the interest rate SWAP entered into in connection with the Previous Financing in an amount of €3.29 million; (5) transaction costs in an amount of approximately €3 million; and (6) an expected special dividend to Talasol’s shareholders in an amount of approximately €30 million.
Sale of Italian indirect wholly-owned subsidiaries (cont’d)
Note 8 - Fixed assets (cont’d)
The Talasol New Financing documents require that security interests be provided in connection with the following: (i) Talasol’s shares (held by the Company’s wholly-owned subsidiary, Ellomay Luxembourg and the other shareholders of Talasol), (ii) pledges over credit rights under certain accounts, (iii) pledges over credit rights under certain Talasol Project’s documents, (iv) pledges over credit rights under the shareholders loans, (v) security assignment of receivables in connection with the PPA, (vi) promissory equipment mortgage and (vii) mortgage on all solar modules and power inverters comprised in the project.
Note 12 – Debentures (cont’d)
Series A Debentures (cont’d)
Series B Debentures (cont’d)
Series C Debentures (cont’d)
In October 2021, the Company issued additional Series C Debentures in an aggregate principal amount of NIS 120,000 thousand (approximately €32,100 thousand) to Israeli classified investors in a private placement for an aggregate gross consideration of approximately NIS 121,600 thousand (approximately €32,529 thousand), reflecting a price of NIS 1.0135 per NIS 1 principal amount.
Series D Convertible Debentures (cont'd)
The Series D Deed of Trust includes customary provisions, including (i) a negative pledge such that the Company may not place a floating charge on all of the Company assets, subject to certain exceptions and (ii) an obligation to pay additional interest for failure to maintain certain financial covenants, with an increase of 0.25% in the annual interest rate for the period in which the Company do not meet each standard and up to an increase of 0.75% in the annual interest rate.
Series D Convertible Debentures (cont’d)
Note 14 - Leases (cont'd)
Compensation to key management personnel and interested parties that are employed by, or provide consulting services to, the Company:
Note 15 - Transactions and Balances with Related Parties (cont'd)
Note 16 - Equity (cont'd)
Composition of share capital (cont'd)
In February 2020, the Company issued 715,000 ordinary shares and warrants to purchase an additional 178,750 ordinary shares to several Israeli institutional investors in a private placement undertaken in accordance with Regulation S of the Securities Act of 1933, as amended. The price per share was set at NIS 70 (approximately €18.9 based on the Euro /NIS exchange rate at that time). The warrants are exercisable for a period of one year, with an exercise price of NIS 80 (approximately €21.6) per ordinary share. The gross proceeds to the Company in connection with the private placement were NIS 50.05 million (approximately €13.5 million based on the Euro /NIS exchange rate at that time). Of the total proceeds, an amount of approximately NIS 1,182 million (approximately €320 thousand based on the Euro/NIS exchange rate at that time) was recognized in other liabilities in connection with these warrants. All of the warrants were exercised during January and February 2021. As a result of the exercises, the Company received gross proceeds of NIS 14,300 thousand (approximately €3,873 thousand based on the Euro /NIS exchange rate at that time).
Note 17 - Share-Based Payment (cont'd)
Stock Option Plans
As of December 31, 2021, options to purchase 10,749 ordinary shares are outstanding and 26,667 ordinary shares are available for future grants under the 1998 Plan.
Changes during the year:
Note 18 - Details of the Statements of Profit or Loss and Other Comprehensive Income (Loss) (Cont'd)
Note 19 - Taxes on Income (cont’d)
Note 21 - Financial Instruments (cont’d)
Fair value (cont'd)
Fair values hierarchy (Cont'd)
Note 22 - Operating Segments (cont’d)
Geographical information (cont’d)
F - 109